189 related articles for article (PubMed ID: 38504095)
21. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder.
Witcher JW; Long A; Smith B; Sauer JM; Heilgenstein J; Wilens T; Spencer T; Biederman J
J Child Adolesc Psychopharmacol; 2003; 13(1):53-63. PubMed ID: 12804126
[TBL] [Abstract][Full Text] [Related]
22. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
Yu G; Li GF; Markowitz JS
J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
[TBL] [Abstract][Full Text] [Related]
23. Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder.
Ghuman JK; Aman MG; Ghuman HS; Reichenbacher T; Gelenberg A; Wright R; Rice S; Fort C
J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):155-66. PubMed ID: 19364293
[TBL] [Abstract][Full Text] [Related]
24. Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.
Fu D; Guo HL; Hu YH; Fang WR; Liu QQ; Xu J; Wu DD; Chen F
Eur J Clin Pharmacol; 2023 Mar; 79(3):349-370. PubMed ID: 36645468
[TBL] [Abstract][Full Text] [Related]
25. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
Ramoz N; Boni C; Downing AM; Close SL; Peters SL; Prokop AM; Allen AJ; Hamon M; Purper-Ouakil D; Gorwood P
Neuropsychopharmacology; 2009 Aug; 34(9):2135-42. PubMed ID: 19387424
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
[TBL] [Abstract][Full Text] [Related]
27. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
Chang K; Nayar D; Howe M; Rana M
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
[TBL] [Abstract][Full Text] [Related]
28. Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Cheng S; Al-Kofahi M; Leeder JS; Brown JT
Clin Pharmacol Ther; 2024 May; 115(5):1033-1043. PubMed ID: 38117180
[TBL] [Abstract][Full Text] [Related]
29. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
[TBL] [Abstract][Full Text] [Related]
31. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder.
Párraga HC; Párraga MI; Harris DK
Int J Psychiatry Med; 2007; 37(4):415-24. PubMed ID: 18441629
[TBL] [Abstract][Full Text] [Related]
32. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.
Didoni A; Sequi M; Panei P; Bonati M;
Eur J Clin Pharmacol; 2011 Oct; 67(10):1061-7. PubMed ID: 21538145
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
[TBL] [Abstract][Full Text] [Related]
34. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
35. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
Treuer T; Gau SS; Méndez L; Montgomery W; Monk JA; Altin M; Wu S; Lin CC; Dueñas HJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):179-93. PubMed ID: 23560600
[TBL] [Abstract][Full Text] [Related]
36. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study.
Hammerness P; Doyle R; Kotarski M; Georgiopoulos A; Joshi G; Zeitlin S; Biederman J
Eur Child Adolesc Psychiatry; 2009 Aug; 18(8):493-8. PubMed ID: 19377865
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men.
Matsui A; Azuma J; Witcher JW; Long AJ; Sauer JM; Smith BP; DeSante KA; Read HA; Takahashi M; Nakano M
J Clin Pharmacol; 2012 Mar; 52(3):388-403. PubMed ID: 21543662
[TBL] [Abstract][Full Text] [Related]
38. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
[TBL] [Abstract][Full Text] [Related]
40. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
Gaillez C; Sorbara F; Perrin E
Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]